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This issue of CME profiles acute viral bronchiolitis – a common 
condition that is often not serious. Nonetheless, each year a number of 
infants, parti cularly those with an underlying susceptibility to severe 
disease, are admitted to hospital or even to paediatric intensive care units. 
This series of articles highlights the diagnostic principles involved, and 
emphasises the principles of management and prevention.
Acute viral bronchiolitis occurs primarily in infants <1 year of 
age. It is frequently the first episode of a wheezing illness in a child. 
This  episode should never be labelled asthma, although it may lead 
to subsequent wheezing and even asthma later in life, which has 
implications for management and certainly for prevention.
Children develop a common cold and then the viruses involved 
may produce inflammation in the lower respiratory tract airways. 
Lower respiratory tract infection, in cases of bronchiolitis, usually 
has a viral aetiology and does not require antibiotic management. 
It is distinguished from pneumonia in that, although producing fast 
breathing, it causes hyperinflation of the chest, which suggests airway 
involvement – not air-space disease. 
Any infant presenting to a doctor with cough and age-specific fast 
breathing, must be assessed for hypoxia. Peripheral oxygen saturation 
is the only test routinely required in such children. If hypoxic, the 
infant must receive oxygen via nasal prongs or face mask and be 
admitted to hospital.
As bacterial co-infection is rare, testing for bacterial involvement 
is unnecessary and unreliable in all but the sickest of children. It also 
implies that therapy should not include the routine use of antibiotics, 
which is unnecessary and potentially dangerous, as the emergence of 
resistant pathogens is an important concern with over-use and abuse 
of these drugs.
Most routine therapies for asthma are ineffective for bronchiolitis 
and should not be used, including bronchodilators (oral and 
nebulised), steroids (oral, systemic or nebulised), montelukast and 
all the over-the-counter cough and cold medicines. A number of 
studies have shown that physiotherapy, which is so popular in South 
Africa (SA), worsens hypoxia, and should therefore be discontinued 
in such cases. While hypertonic saline nebulisation was suggested 
as an effective therapy for bronchiolitis, reducing the need for and 
duration of hospitalisation, recent large studies have shown that it is 
ineffective. It should therefore not be recommended.
There are important preventive modalities for bronchiolitis, 
including isolation of children with colds (i.e. sick children should 
not go to crèches for a few days), and teaching children (and 
adults looking after infants) to practise sneeze and cough hygiene. 
Prevention does not include the use of prophylactic antibiotics for 
children with upper respiratory tract infections; their use is strongly 
discouraged.
Prevention of respiratory syncytial virus (RSV) disease in young 
children may be the most effective strategy to reduce the burden 
of disease, especially in children at high risk of developing severe 
disease.[1] The monoclonal antibody, palivizumab, administered 
monthly throughout the RSV season to infants and children at 
high risk of severe RSV disease, has been shown to be effective 
for prevention. Furthermore, palivizumab has also been proven to 
reduce RSV disease, wheezing and recurrent wheezing episodes in 
the first year of life when administered to late preterm infants.[2] 
However, its use is limited by its high cost and the need for monthly 
intramuscular injections during the RSV season. More recently, 
increased attention has been given to the development of an effective 
RSV vaccine, particularly targeted at pregnant women, as a strategy 
for prevention of RSV disease in their offspring in the first months 
of life.[3] This is an attractive strategy for which the results of clinical 
trials are awaited.
The two CME articles in this edition of SAMJ are a concise 
reflection of the evidence with regard to acute viral bronchiolitis. The 
guideline committee has reviewed the available literature in making 
these recommendations. Each section has been fully referenced. The 
first article[4] gives a step-wise approach to the diagnosis of acute 
viral bronchiolitis, suggesting that ‘less is more’ by way of tests in 
patients with this condition; that many tests are inappropriate; and 
that important tests such as peripheral oxygen saturation must be 
appropriately performed. The second article[5] is a summary of what 
should be used with regard to treatment and prevention.
A number of guidelines for the management and prevention of 
acute viral bronchiolitis are published worldwide annually. These 
have been consulted in our recommendations. However, none 
perfectly fits the disease entity, organism seasonality, duration and 
specific considerations for SA. Hence the need for local guidelines 
on this topic. It is hoped that these will guide local healthcare 
practitioners, funders and policy makers in ensuring the best care of 
children in SA.
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